The Rotterdam Study: Objectives and design update

European Journal of Epidemiology

Volumn 22, Issue 11, 2007, Pages 819-829

  Hofman, Albert ^a   Breteler, Monique M B ^a   Van Duijn, Cornelia M ^a   Krestin, Gabriel P ^a   Pols, Huibert A ^a   Stricker, Bruno H Ch ^a   Tiemeier, Henning ^a   Uitterlinden, André G ^a   Vingerling, Johannes R ^a   Witteman, Jacqueline C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer disease; Cohort study; Dementia; Diabetes; Genome wide analysis; Glaucoma; Heart failure; Macular degeneration; Myocardial infarction; Osteoporosis; Parkinson disease; Pharmaco epidemiology; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT; ZINC;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; BRAIN RADIOGRAPHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DEGENERATIVE DISEASE; DEMOGRAPHY; DEPRESSION; DIETARY INTAKE; DRUG SAFETY; ENDOCRINE DISEASE; EPIDEMIOLOGICAL DATA; EYE DISEASE; GENETIC RISK; GENOME ANALYSIS; GENOTYPE; GRIEF; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOTHYROIDISM; INFLAMMATION; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MENTAL DISEASE; METABOLISM; METHODOLOGY; NETHERLANDS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NUTRITION; OPEN ANGLE GLAUCOMA; PARKINSON DISEASE; PARKINSONISM; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; QT PROLONGATION; RETINA MACULA AGE RELATED DEGENERATION; SLEEP DISORDER; STROKE;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COHORT STUDIES; EPIDEMIOLOGIC RESEARCH DESIGN; GENETIC RESEARCH; HUMANS; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NETHERLANDS; PHARMACOEPIDEMIOLOGY;

EID: 36148941777     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-007-9199-x     Document Type: Article

References (91)

1. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science 2002;296:1029-31.
2. Peto R, Doll R. There is no such thing as aging. BMJ 1997;315:1030-2.
3. Hofman A, Grobbee DE, de Jong PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Study. Eur J Epidemiol 1991;7:403-22.
4. Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A, Witteman JCM. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132:270-8.
5. Schuit SCE, Oei HHS, Witteman JCM, Geurts Van Kessel CH, Van Meurs JBJ, Nijhuis RL, Van Leeuwen JPTM, De Jong FH, Zillekens MC, Hofman A, Pols HAP, Uitterlinden AG. Estrogen receptor α gene polymorphisms and risk of myocardial infarction. JAMA 2004;291:2969-77.
6. Kardys I, De Maat MP, Uitterlinden AG, Hofman A, Witteman JC. C-reactive protein gene haplotypes and risk of coronary heart disease. The Rotterdam Study. Eur Heart J 2006;27:1331-7.
7. Oei HH, Van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570-5.
8. Kardys I, Klaver CC, Despriet DD, Bergen AA, Uitterlinden AG, Hofman A, Oostra BA, Van Duijn CM, De Jong PT, Witteman JC. A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction. The Rotterdam Study. J Am Coll Cardiol 2006;47:1568-75.
9. Van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004;109:1089-94.
10. Mattace-Raso FUS, Van der Cammen TJM, Hofman A, Van Popele NM, Bos ML, Schalekamp MADH, Asmar R, Reneman RS, Hoeks A, Breteler MMB, Witteman JCM. Arterial stiffness and risk of coronary heart disease and stroke. The Rotterdam Study. Circulation 2006;113:657-63.
11. Vliegenthart R, Oudkerk M, Hofman A, Oei HHS, van Dijck W, van Rooij F, Witteman JCM. Coronary calcification improves cardiovascular risk prediction in a population of older adults. Circulation 2005;112:572-7.
12. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure the Rotterdam Study. Eur Heart J 2004;25:1614-9.
13. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
14. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Rooij FJA, Lip GYH, Witteman JCM. Subclinical atherosclerosis and risk of atrial fibrillation. Arch Intern Med 2007;167:382-7.
15. Van Vark LC, Kardys I, Bleumink GS, Knetsch AM, Deckers JW, Hofman A, Stricker BH, Witteman JC. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. Eur Heart J 2006;27:2346-52.
16. Ott A, Breteler MMB, van Harskamp F, Claus JJ, van der Cammen TJM, Grobbee DE, Hofman A. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995;310:970-3.
17. de Rijk MC, Breteler MMB, Graveland GA, Ott A, Grobbee DE, van der Meché FGA, Hofman A. Prevalence of Parkinson's disease in the elderly. The Rotterdam Study. Neurology 1995;45:2143-6.
18. Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MMB. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001;22:575-80.
19. de Lau LML, Giesbergen PCLM, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MMB. Incidence of parkinsonism and Parkinson's disease in a general population: the Rotterdam Study. Neurology 2004;63:1240-4.
20. Hollander M, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Breteler MMB. Incidence, risk and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2003;74:317-21.
21. Breteler MMB, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and the distribution of cognitive function in an elderly population. The Rotterdam Study. BMJ 1994;308:1604-8.
22. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, van Duijn CM, van Broeckhoven C, Grobbee DE. Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-4.
23. Ott A, Slooter AJC, Hofman A, van Harskamp F, Witteman JCM, van Broeckhoven C, van Duijn CM, Breteler MMB. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-3.
24. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JCM, Breteler MMB. Dietary intake of antioxidants and risk of Alzheimer's disease: the Rotterdam Study. JAMA 2002;287:3223-9.
25. Ruitenberg A, van Swieten JC, Witteman JCM, Mehta KM, van Duijn CM, Hofman A, Breteler MMB. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002;359:281-6.
26. In 't Veld BA, Ruitenberg A, Launer LJ, van Duijn CM, Hofman A, Stijnen Th, Breteler MMB, Stricker BHCh. NSAID and the risk of Alzheimer's disease or vascular dementia. The Rotterdam Study. N Engl J Med 2001;345:1515-21.
27. Hollander M, Bots ML, Iglesias del Sol A, Koudstaal PJ, Witteman JCM, Grobbee DE, Hofman A, Breteler MMB. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam Study. Circulation 2002;105:2872-7.
28. Bos MJ, Schipper CMA, Koudstaal PJ, Witteman JCM, Hofman A, Breteler MM. High plasma C-reactive protein level is not an independent predictor for stroke. The Rotterdam Study. Circulation 2006;114:1591-8.
29. Vermeer SE, den Heijer T, Prins ND, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. The Rotterdam Scan Study. N Engl J Med 2003;348:1215-22.
30. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJPE, Hofman A, Krestin GP, Niessen WJ, Breteler MMB, Van der Luyt A. Incidental findings on brain MRI in the general population N Engl J Med 2007 (in press).
31. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MMB. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000;57:1071-6.
32. Den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MMB. Use of hippocampal and amygdalar volumes on MRI to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 2006;63:57-62.
33. Breteler MMB, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JHW, van Harskamp F, Tanghe HLJ, de Jong PTVM, van Gijn J, Hofman A. Cerebral white matter lesions, vascular risk factors and cognitive function in a population-based study. Neurology 1994;44:1246-52.
34. Tiemeier H, Dijck van W, Hofman A, Witteman JCM, Stijnen T, Breteler MMB. Atherosclerosis and late life depression are related. The Rotterdam Study. Arch Gen Psychiatry 2004;61:369-76.
35. Tiemeier H, Bakker SLM, Hofman A, Koudstaal PJ, Breteler MMB. Cerebral haemodynamics and depression in the elderly. J Neurol Neurosurg Psychiatry 2002;73:34-39.
36. Naarding P, Tiemeier H, Breteler MM, Schoevers RA, Jonker C, Koudstaal PJ, Beekman AT. Clinically defined vascular depression in the general population. Psychol Med 2007;37:383-92.
37. Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MMB. Plasma fatty acid composition and depression in the elderly are associated: the Rotterdam Study. Am J Clin Nutr 2003;78:40-6.
38. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MMB. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002;159:2099-101.
39. Tiemeier H, Hofman A, Kiliaan AJ, Meijer J, Breteler MMB. Vitamin E and depressive symptoms are not related. The Rotterdam Study. J Affect Disord 2002;72:79-83.
40. Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler MMB. Inflammatory proteins and depression in the elderly. Epidemiology 2003;14:103-7.
41. Tiemeier H, Schuit SC, den Heijer T, van Meurs JB, van Tuijl HR, Hofman A, Breteler MM, Pols HA, Uitterlinden AG. Estrogen receptor alpha gene polymorphisms and anxiety disorder in an elderly population. Mol Psychiatry 2005;10:806-7.
42. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-410.
43. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R. Scan: schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 1990;47:589-93.
44. Wittchen HU, Lachner G, Wunderlich U, Pfister H. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 1998;33:568-78.
45. van den Berg JF, Tulen JHM, Neven AK, Hofman A, Miedema HME, Witteman JCM, Tiemeier H. Sleep duration and hypertension are not associated in the elderly. Hypertension 2007;50:585-9.
46. Prigerson HG, Maciejewski PK, Reynolds CF 3rd, Bierhals AJ, Newsom JT, Fasiczka A, Frank E, Doman J, Miller M. Inventory of complicated grief: a scale to measure maladaptive symptoms of loss. Psychiatry Res 1995;59:65-79.
47. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998;116:653-8.
48. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol 1996;114:1193-6.
49. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol 1995;142:404-9.
50. Ikram MK, van Leeuwen R, Vingerling JR, Hofman A, de Jong PT. Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3778-82.
51. Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet 1998;63:200-6.
52. Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1646-51.
53. Assink JJ, Klaver CC, Houwing-Duistermaat JJ, et al. Heterogeneity of the genetic risk in age-related macular disease: a population-based familial risk study. Ophthalmology 2005;112:482-7.
54. van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255-6.
55. Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006;296:301-9.
56. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 1994;101:1851-5.
57. Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences: the Rotterdam Study. Invest Ophthalmol Vis Sci 2000;41:3309-21.
58. Dielemans I, Vingerling JR, Algra D, Hofman A, Grobbee DE, de Jong PT. Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study. Ophthalmology 1995;102:54-60.
59. Wolfs RC, Klaver CC, Ramrattan RS, van Duijn CM, Hofman A, de Jong PT. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1640-5.
60. de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de Jong PT. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005;112:1487-93.
61. Skenduli-Bala E, de Voogd S, Wolfs RC, et al. Causes of incident visual field loss in a general elderly population: the Rotterdam study. Arch Ophthalmol 2005;123:233-8.
62. Ikram MK, de Jong FJ, Vingerling JR, et al. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci 2004;45:2129-34.
63. Rietveld I, Ikram MK, Vingerling JR, et al. An igf-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 2006;55:2387-91.
64. Ikram MK, de Jong FJ, Bos MJ, et al. Retinal vessel diameters and risk of stroke: the Rotterdam Study. Neurology 2006;66:1339-43.
65. Ikram MK, Witteman JC, Vingerling JR, Breteler MM, Hofman A, de Jong PT. Retinal vessel diameters and risk of hypertension: the Rotterdam Study. Hypertension 2006;47:189-94.
66. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-74.
67. Hubbard LD, Brothers RJ, King WN, et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106:2269-80.
68. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.
69. Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 2002;359:1036-7.
70. van Meurs JBJ, Schuit SCE, Weel AEAM, van der Klift M, Bergink AP, Arp PP, Colin EM, Fang Y, Hofman A, van Duijn CM, van Leeuwen JPTM, Pols HAP, Uitterlinden AG. Association of 5′ estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area, and fracture risk. Hum Mol Genet 2003;12:1745-54.
71. Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, de Maat MP, Boekhoorn SS, Vingerling JR, Hofman A, Oostra BA, Uitterlinden AG, Stijnen T, van Duijn CM, de Jong PT. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006;296:301-9.
72. Aarnoudse AJLHJ, Newton-Cheh C, de Bakker PIW, Straus SMJM, Kors JA, Hofman A, Uitterlinden AG, Witteman JCM, Stricker BHCh. A common NOS1AP variant is associated with longer QTc interval and sudden cardiac death: the Rotterdam Study. Circulation 2007;116:10-6.
73. Fang Y, van Meurs JB, d'Alesio A, Jhamai M, Zhao H, Rivadeneira F, Hofman A, van Leeuwen JP, Jehan F, Pols HA, Uitterlinden AG. Promoter and 3′ UTR haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam Study Am J Hum Genet 2005;77:807-23.
74. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. Bioinformatics 2007 (in press).
75. In 't Veld BA, Ruitenberg A, Hofman A, Stricker BHCh, Breteler MMB. Antihypertensive drugs and incidence of dementia: the Rotterdam study. Neurobiol Aging 2001;22:407-12.
76. Feenstra J, Heerdink ER, Grobbee DE, Stricker BHCh. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch Int Med 2002;162:265-70.
77. Straus SM, Kors JA, de Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom JCM, Stricker BHCh, Witteman JCM. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362-7.
78. Van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JCM, Kingma JH, Sturkenboom MCJM, Stricker BHCh. Corticosteroids and the risk of atrial fibrillation. Arch Int Med 2006;165:1016-20.
79. Schoofs MWCJ, van der Klift M, Hofman A, de Laet CEDH, Herings RMC, Stijnen Th, Pols HAP, Stricker BHCh. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003;139:476-82.
80. Schoofs MW, Sturkenboom MCJM, van der Klift M, Hofman A, Pols HA, Stricker BHCh. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 2004;19:1525-30.
81. Reijman M, Bierma-Zeinstra SM, Pols HAP, Koes BW, Stricker BHCh, Hazes JM. Is there an association between the use of different types of NSAIDs and radiologic progression of osteoarthritis ? The Rotterdam Study. Arthritis Rheum 2005;52:3137-42.
82. Van Leeuwen R, Vingerling JR, Hofman A, de Jong PTVM, Stricker BHCh. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255-6.
83. Visser LE, Penning-van Beest FJA, Kasbergen AAH, De Smet PAGM, Vulto AG, Hofman A, Stricker BHCh. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther 2002;71:496-502.
84. Visser LE, Penning-van Beest FJA, Kasbergen HAA, De Smet PAGM, Vulto AG, Hofman A, Stricker BHCh. Overanticoagulation associated with combined use of antibacterial agents and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002;88:705-10.
85. Visser LE, van Vliet M, van Schaik RHN, Kasbergen AAH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BHCh. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004;14:27-33.
86. Visser LE, Penning-van Beest FJ, Wilson JHP, Vulto AG, Kasbergen AA, de Smet PAGM, Hofman A, Stricker BHCh. Overanticoagulation associated with combined use of lactulose and coumarin anticoagulants. Br J Clin Pharmacol 2004;57:522-4.
87. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BHCh. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004;92:61-6.
88. Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BHCh. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol 2004;127:85-9.
89. Visser LE, van Schaik RHN, van Vliet M, Trienekens PH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BHCh. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005;77:479-85.
90. Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A, Kingma JH, Witteman JC, Stricker BHCh. Mortality in patients with hypertension on ACE-inhibitor treatment is influenced by the ACE I/D polymorphism. Pharmacogenet Genomics 2005;15:75-81.
91. Visser LE, Trienekens PH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BHCh. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 2005;15:69-74.